生物科技公司 VERAXA 在納斯達克上市交易
Biotech firm VERAXA starts trading on Nasdaq
Updated at: June 11, 2026 at 12:35 PM
2026年6月11日，總部設於蘇黎世的VERAXA Biotech AG正式進入公開市場，以股票代號「VRXA」在納斯達克資本市場開始交易。
On June 11, 2026, Zurich-based VERAXA Biotech AG officially entered the public market, beginning trade on the Nasdaq Capital Market under the ticker symbol 'VRXA'.
源自歐洲分子生物實驗室(EMBL)研究的VERAXA專精於腫瘤學。
Their proprietary BiTAC technology acts as a biological 'AND gate,' ensuring that immune responses are triggered only when two tumor markers are present.
其專有的BiTAC技術扮演著生物學上的「及閘」(AND gate)角色，確保僅在偵測到兩個腫瘤標記時才啟發免疫反應。
This approach aims to maximize the destruction of solid tumors while sparing healthy tissue.
此方法旨在最大限度地破壞實體腫瘤，同時保護健康組織。
As a pre-commercial firm, VERAXA is currently focused on advancing its antibody-based therapeutics, including bispecific T-cell engagers and antibody-drug conjugates.
在透過票據融資與股份購買協議獲得額外資金後，該公司現在面臨關鍵挑戰，即需透過臨床試驗來證明其創新產品線的功效。
